NIH
NIH company profile
Latest price
As of — · Market data by Massive
Market cap
—
Volume
—
Previous close
—
Day range
—
Listed
—
Coverage
6 articles
Price performance
Recent trading
Newsroom
Latest NIH coverage
New study finds childhood abuse linked to higher risk for high cholesterol as an adult
[ad_1] ***Content Warning: The following news release includes descriptions and discussion about child abuse and may be triggering for some readers. Research Highlights: The likelihood of developing high cholesterol – a risk factor for heart disease and stroke – was higher among white men and white women who experienced abuse during childhood, according to a
Mechanical clot removal may restore more function than medication alone after severe stroke
[ad_1] Research Highlights: Patients with severe strokes, caused by artery-blocking clots, who had endovascular therapy (clots mechanically removed) in addition to standard medical therapy had fewer physical limitations or challenges 90 days after the stroke compared to those who received standard medical therapy alone, according to a randomized study in Jap
Heart risk 'calculators' overlook increased risk for people of South Asian ancestry
[ad_1] Research Highlights: When compared to individuals of European ancestry, South Asians had a more than two-fold risk of developing heart disease. Risk calculators used by clinicians to guide decisions about preventing or treating heart disease do not always reflect the increased cardiac risks faced by people of South Asian descent. To gain .
GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development
[ad_1] Company Focused on Single-dose Vaccine Against Multiple COVID Strains Atlanta, GA – (NewMediaWire) – January 11, 2021 – GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that the National Institute of Allergy and Infectious Dise
GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development
[ad_1] Atlanta, GA – (NewMediaWire) – November 30, 2020 – GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the signing of a Patent and Biological Materials License Agreement (the “License Agreem
Interactive Map Displays Strength of Industry’s National Footprint
[ad_1] BIO’s biennial financial growth and jobs report focuses on the financial progress and nationwide footprint of the bioscience business. As the business’s go-to useful resource for efficiency, positioning and traits, this necessary reference device for advocacy and messaging demonstrates the worth of the business’s constant file of producing high-qualit